The biotech startup ResBiotic has created a lung disease-focused pharmaceutical spin-off — Alveolus Bio — and launched its first probiotic-based consumer health product called resB Lung Support. The parent company, based in Birmingham, Alabama, and its subsidiary are using $4.5 million in seed funding “to transform the respiratory care landscape…
ResBiotic Subsidiary Alveolus Bio Focused on Lung, Gut Health
Vitamin D lessenened lung scarring (fibrosis) in a mouse model of idiopathic pulmonary fibrosis (IPF) by suppressing the activity of the PSAT1 enzyme, and subsequently the mitogen-activated protein kinase (MAPK) pathway, a study shows. PSAT1 is an enzyme that links metabolic and amino acid production pathways. The MAPK pathway is…
A protein called RAGE may be a useful biomarker for the diagnosis and prognosis of idiopathic pulmonary fibrosis (IPF), a recent study suggests. RAGE levels were found to be decreased in the lungs of IPF patients, and in those of mice used to model the human disease. Meanwhile, the…
Growing up as an only child, I’ve spent my whole life hearing what one Washington Post writer calls “a slew of profoundly unflattering and occasionally contradictory stereotypes.” I’ve been told many times how lucky I am that I don’t have to share my parents’ affection with siblings. Or…
Agomab Therapeutics and Origo Biopharma are joining forces to develop new therapies for pulmonary fibrosis (PF) and other conditions caused by excessive tissue scarring, or fibrosis. “Agomab and Origo share a common vision that targeting growth factors has tremendous disease-modifying potential,” Tim Knotnerus, Agomab’s CEO, said in…
My mom, Diana, has this endearing way of summarizing books she’s read or movies she’s seen by reducing entire plotlines to who’s in love with whom. As someone who’s studied the craft of storytelling, I have a hard time hearing great works of art being reduced to…
Healthcare providers should broach the topic of palliative care — specialized care that may or may not include hospice — with pulmonary fibrosis (PF) patients shortly after they are diagnosed, according to a position statement recently issued by the Pulmonary Fibrosis Foundation (PFF). “Soon after diagnosis, discussions of…
In May 2017, I began the roller coaster ride that was my lung transplant evaluation. I call it this because it had the usual climbs of positive developments, and the fast and dramatic drops. But it also had terrifying twists and turns, and unexpected events, which left me frustrated…
Smoking cigarettes substantially increases the risk of developing idiopathic pulmonary fibrosis (IPF), according to a population-based study conducted in Korea. The findings indicate the risk of IPF is greater in current smokers, compared with people who used to smoke but have since quit. The study, “Impact…
Oncodesign and TiumBio have partnered to develop therapies for various diseases caused by fibrosis, or tissue scarring, including pulmonary fibrosis (PF). Under the collaboration, the French company Oncodesign will identify, produce, optimize, and conduct early stage analysis of therapeutic candidates generated from Nanocyclix — a technology…
